Phase I study in patients with pancreatic or ovarian cancer
Saturday, May 31, 2014 - 01:31
in Health & Medicine
In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity. The drug is in fact a combination of a chemotherapeutic agent with an antibody, technically called an antibody-drug conjugate (ADC).